Strain Profile
Save

Streptococcus salivarius 24SMB

◔ Human-origin
Sequenced
Public genome assembly available

Streptococcus salivarius 24SMB is an upper respiratory tract commensal studied primarily as a nasal spray "bacteriotherapy" — a term referring to the deliberate introduction of beneficial bacteria to compete with pathogens at mucosal surfaces. Multiple observational studies and at least one randomized controlled trial in pediatric populations have examined intranasal administration of 24SMB combined with Streptococcus oralis 89a in connection with recurrent acute otitis media (middle ear infections) and upper respiratory tract infections. In vitro work has examined 24SMB's interactions with biofilm formation by common respiratory pathogens. The evidence base is primarily observational and pediatric; findings should not be generalized to other populations or delivery routes without further study. These are research topics, not findings; the papers do not establish that this strain treats or prevents any condition.

Where it's been studied

Share of this strain's 12 body-system-tagged papers that concern each system. Research coverage, not measured effect.

Symptoms in the research

Share of this strain's 11 symptom-tagged papers that mention each symptom or condition. Research coverage, not evidence of benefit.

Research

15 papers reference this strain in the probiotic database.

Match confidence
2023 RCT
Topical administration of S. salivarius 24SMB-S. oralis 89a in children with adenoidal disease: a double-blind controlled trial
· European Journal of Pediatrics
2022 REVIEW
A Brief Review of Local Bacteriotherapy for Preventing Respiratory Infections
· Allergies
2020 OBSERVATIONAL
Bacteriotherapy with Streptococcus salivarius 24SMB and Streptococcus oralis 89a nasal spray for treatment of upper respiratory tract infections in children: a pilot study on short-term efficacy
· ˜The œItalian Journal of Pediatrics/Italian journal of pediatrics
2020 OBSERVATIONAL
Oral bacteriotherapy in children with recurrent respiratory infections: a real-life study.
· PubMed
2019 REVIEW
An overview on upper respiratory tract infections and bacteriotherapy as innovative therapeutic strategy.
· PubMed
2019 OBSERVATIONAL
The efficacy and tolerability of Streptococcus salivarius 24SMB and Streptococcus oralis 89a administered as nasal spray in the treatment of recurrent upper respiratory tract infections in children.
· PubMed
2019 OBSERVATIONAL
The role of bacteriotherapy in the prevention of adenoidectomy.
· PubMed
2019 OBSERVATIONAL
Bacteriotherapy in children with recurrent upper respiratory tract infections.
· PubMed
2018 IN_VITRO
Probiotics Streptococcus salivarius 24SMB and Streptococcus oralis 89a interfere with biofilm formation of pathogens of the upper respiratory tract
· BMC Infectious Diseases
2018 OBSERVATIONAL
Bacteriotherapy for preventing recurrent upper respiratory infections in children: a real-world experience
· Otolaryngologia Polska
2018 OBSERVATIONAL
Multicentric study on the efficacy and tolerability of Streptococcus salivarius 24SMB and Streptococcus oralis 89a in respiratory tract infections
· Romanian Journal of Rhinology
2017 OBSERVATIONAL
Bacteriotherapy with Streptococcus salivarius 24SMB and Streptococcus oralis 89a nasal spray for preventing recurrent acute otitis media in children: a real-life clinical experience
· International Journal of General Medicine
2017 OBSERVATIONAL
Bacteriotherapy with Streptococcus salivarius 24SMB and Streptococcus oralis 89a nasal spray for preventing recurrent acute otitis media in children: a real-life clinical experience
· DOAJ (DOAJ: Directory of Open Access Journals)
2012 IN_VITRO
Bacteriocin-producing oral streptococci and inhibition of respiratory pathogens
· FEMS Immunology & Medical Microbiology
2024 REVIEW
Streptococcus salivarius Role as a Probiotic in Children’s Health and Disease Prophylaxis—A Systematic Review
· Life
Browse all 15 papers →

Discussion

Be the first to comment.

Sign in to join the discussion.

No comments yet.

Citations

Selected papers that name this strain.

  1. [1]
    Topical administration of S. salivarius 24SMB-S. oralis 89a in children with adenoidal disease: a double-blind controlled trial
    · European Journal of Pediatrics · 2023
    PMID 37874401 →